Generic Medicine Info
Should be taken with food.
Hypersensitivity to sulfinpyrazone and other pyrazolone derivatives. Patient in whom attacks of asthma, urticaria or acute rhinitis are precipitated by aspirin or other drugs w/ prostaglandin-synthetase inhibiting activity. Acute gout attack, blood coagulation disorders, uric acid renal calculi, porphyria, peptic ulceration, severe parenchymal lesions of liver or kidneys, blood dyscrasias. Severe hepatic and renal impairment. Concomitant use w/ salicylates.
Special Precautions
Patient w/ heart failure. Mild to moderate renal impairment. Pregnancy and lactation. Patient Counselling Ensure adequate fluid intake (approx 2-3 L/day) and urine alkalinisation. Monitoring Parameters Monitor renal function, blood count.
Adverse Reactions
Nausea, vomiting, diarrhoea, abdominal pain, GI bleeding, rashes, aplastic anaemia, agranulocytosis, leucopenia, thrombocytopenia, raised liver enzymes, jaundice, hepatitis, renal impairment, salt and water retention, acute renal failure.
Drug Interactions
Decreased therapeutic effect when given w/ drugs that increase uric acid concentration (e.g. diuretics, pyrazinamide). May potentiate the action of coumarin anticoagulants (e.g. warfarin, acenocoumarol), hypoglycaemic agents and sulfonamides. May decrease plasma levels of theophylline. May increase plasma levels of penicillins and phenytoin. Increased risk of haemorrhage w/ substances affecting homeostasis (e.g. non-steroidal antirheumatic drugs). Probenecid may inhibit renal tubular secretion of sulfinpyrazone.
ATC Classification
M04AB02 - sulfinpyrazone ; Belongs to the class of preparations increasing uric acid excretion. Used in the treatment of gout.
Disclaimer: This information is independently developed by CIMS based on sulfinpyrazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in